Eiger BioPharmaceuticals Announces Peginterferon Lambda to be Added to Multi-Center Phase 3 TOGETHER COVID-19 Study in Brazil

Category Primary study
Web pagePress release - PR Newswire - May 03, 2021, 08:00 ET
Year 2021

This article is not included in any systematic review

This article is part of the following publication threads:
Loading references information
This article has no abstract
Epistemonikos ID: 3d854d4e94d1b15bb2a872a27f93fa24fe1e5b40
First added on: Jul 28, 2021